Updated:
Todos Medical Ltd.
Todos Medical Ltd. is a New York-based diagnostic company developing blood tests for early cancer detection using circulating tumor cell analysis.
Todos Medical Ltd.
Todos Medical Ltd. was formed to commercialize a diagnostic platform originating from Israeli research institutions. The company's lead product, TMB-1, is a blood test designed to detect circulating tumor cells (CTCs) and tumor-associated antigens across a broad range of cancers, including breast, colorectal, and lung (per public SEC filings, 2021). Taxi to strategy centers on a proprietary assay that measures immune response to tumor markers. The platform is intended for both early detection and treatment monitoring, particularly for patients undergoing immunotherapy. The firm has disclosed collaborations with CLIA-certified labs and academic medical centers in the United States and Israel (per corporate presentations, 2020). Geographic focus is North America and the Middle East, with research ties to Tel Aviv University. Team size and investment professionals are not publicly disclosed; the firm operates as a publicly traded entity (OTC: TOMDF) with a small corporate staff. No additional offices beyond New York are confirmed. The company has pursued regulatory clearance through the FDA’s Breakthrough Device designation pathway (per company press releases, 2022). No recent operational events of scale were identified within the last 24 months. Todos Medical is structurally distinct as a publicly traded diagnostic developer rather than a typical family-office asset manager. Its capital structure relies on equity offerings and research grants, not private family capital. The firm has not disclosed any relationship with a family office or wealth origin.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
What is Todos Medical's core diagnostic product?
The firm's primary offering is the TMB-1 blood test, which detects circulating tumor cells (CTCs) and tumor-associated antigens. It is designed for early screening of multiple cancer types, including breast, colorectal, and lung cancers (per SEC filings, 2021).
Is Todos Medical a family office or traditional investment firm?
Todos Medical is a publicly traded diagnostics company (OTC: TOMDF), not a family office or asset management firm. Its funding comes from equity offerings and research grants, not from a family wealth pool.
Where does Todos Medical conduct its research and development?
The company's R&D is primarily based in Israel, with ties to Tel Aviv University and CLIA-certified labs in the United States. Commercial operations are headquartered in New York (per corporate presentations, 2020).
Has Todos Medical received FDA approval for its test?
As of public records through 2022, the company had not received full FDA approval for TMB-1. It pursued the FDA's Breakthrough Device designation, which expedites review for novel diagnostic technologies (per company press releases, 2022).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: